Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
REGULATORY
2 Women Die after BA.5 COVID Booster Shots: MHLW
The Ministry of Health, Labor and Welfare (MHLW) said on November 11 that two women, aged 42 and 87, had passed away after receiving the COVID-19 booster tailored for the BA.5 Omicron variant. The two deaths were reported at a…
To read the full story
Related Article
- MHLW Panel OKs 192 More Health Damage Claims for COVID-19 Vaccines
April 24, 2023
- Relief Claims OK’ed for 12 More Deaths Possibly Linked to COVID Jabs
April 18, 2023
- MHLW Panel OKs 184 More Health Damage Claims for COVID-19 Jabs
March 22, 2023
- Japan Damage Relief Panel Recognizes 11 More Deaths Possibly Tied to COVID Jabs
March 16, 2023
- Japan Safety Panels Recognize 1st Death Tied to COVID Vaccine
March 13, 2023
- Japan Panel Recognizes 10 More Deaths Possibly Linked to COVID Jabs
February 13, 2023
- MHLW Panel OKs 79 More Health Damage Claims for COVID-19 Vaccines
February 8, 2023
- MHLW Panel OKs 62 More Health Damage Claims for COVID-19 Vaccines
January 24, 2023
- MHLW Panel OKs 64 More Health Damage Claims for COVID-19 Vaccines
January 16, 2023
- Japan Panel Recognizes 5 More Deaths Possibly Tied to COVID Vaccines
January 13, 2023
- Japan to Boost Review of Health Damage Claims for COVID-19 Vaccines
January 12, 2023
- MHLW Panel OKs 70 More Health Damage Claims for COVID-19 Vaccines
December 26, 2022
- Japan Panel Recognizes 5 More Deaths Possibly Linked to COVID Jabs, 1st for 20s
December 13, 2022
REGULATORY
- Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
- Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
August 12, 2025
- Japan Approves FY2026 Budget Guidelines, Natural Increase at 400 Billion Yen
August 12, 2025
- PMDA Flags New Potential Risks for RAS Agents and Others
August 12, 2025
- Japan Approves MSD’s 21-Valent Pneumococcal Vaccine
August 8, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…